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Tbjective: The treatment of non–small cell lung cancer depends on the stage, and
his is clinically best determined by using fluorodeoxyglucose–positron emission
omography/computed tomography. We evaluated the effect smoking has on the
ccuracy of this test.
ethods: We performed a prospective cohort study evaluating the accuracy of
linical stage compared with pathologic stage between cigarette smokers and
onsmokers with non–small cell lung cancer. All patients were assigned a clinical
NM stage after fluorodeoxyglucose–positron emission tomographic/computed to-
ographic scanning and then underwent meticulously pathologic TNM staging. If
2, N3, or M1 negative, patients underwent thoracotomy with complete thoracic
ymphadenectomy. The clinical and pathologic stages were compared.
esults: There were 246 patients: 52 never smoked (NS group), 112 quit at least 1
onth before fluorodeoxyglucose–positron emission tomography/computed tomog-
aphy (Q group), and 82 were still smokers (S group). The 3 groups were similar for
tage and histology. The overall accuracy was 83%, 80%, and 64% for the NS, Q,
nd S groups, respectively (P  .03). The accuracy for the T status was 88%, 84%,
nd 86%; accuracy for the N2 lymph nodes was 96%, 75%, and 72%; and accuracy
or the N1 lymph nodes was 92%, 78%, and 80%, respectively, favoring the NS
roup. The greater the pack-year history, the greater the N2 inaccuracy (P  .04).
ultivariate analysis showed that status of smoking (P  .026) and maxSUV value
P  .014) were independent predictors of fluorodeoxyglucose–positron emission
omography/computed tomography accuracy.
onclusions: Patients with non–small cell lung cancer who continue to smoke at the
ime of their fluorodeoxyglucose–positron emission tomographic/computed tomo-
raphic scan have less accurate clinical staging compared with those who stopped
month before or who never smoked. As the pack-years increase, the accuracy for
he N2 nodes decrease. Nonsmokers have the most accurate clinical staging.
he treatment of non–small cell lung cancer (NSCLC) depends on the
clinical stage that is often generated based on the result of an integrated
fluorodeoxyglucose–positron emission tomographic/computed tomographic
can (FDG-PET/CT).1 A dedicated positron emission tomographic (PET) scan now
robably represents the new standard of care for noninvasive staging in patients with
uspected or biopsy-proved NSCLC. We and others have shown that even though
ntegrated FDG-PET/CT is the most accurate clinical staging tool currently avail-
ble, it often is wrong when compared with the actual pathologic stage.2-5
The purpose of this study was to determine whether the staging accuracy of
ntegrated FDG-PET/CT scanning was affected by cigarette smoking status. Thus
he Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 6 1363
wr
s
P
d
p
M
P
T
t
m
g
c
w
r
o
b
t
d
s
R
F
s
W
r
P
t
w
t
I
f
f
(
n
(
i
t
M
a
i
w
t
P
A
s
c
t
c
t
T
C
M
S
R
M
M
M
P
Q
P
E
m
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1
G
TSe evaluated accuracy in patients who never smoked ciga-
ettes, those who quit at least 1 month before their PET
can, and those who were still smoking at the time of their
ET scan. In addition, we also sought to evaluate whether a
ose-response relationship exists between accuracy and
ack-years smoked.
ethods
atient Selection
his is a prospective cohort study. Patients who presented to one
horacic surgeon over a 2-year period with an indeterminate pul-
onary nodule or biopsy-proved NSCLC who underwent inte-
rated FDG-PET/CT at the University of Alabama at Birmingham
enter were eligible for this study. Patients were excluded if they
ere less than 19 years old, had a history of type I diabetes, and/or
eceived preoperative chemotherapy or radiation. The University
f Alabama at Birmingham’s institutional review board approved
oth the electronic prospective database used for this study and
his prospective trial. Patient consent was obtained to enter their
ABLE 1. Patient characteristics
haracteristic
Never smoked,
n  52
edian age (y) 55.3 8.2
ex
Male 20 (38%)
Female 32 (62%)
ace
White 48 (92%)
Black 4 (8%)
ean ECOG score 0.1
edian packs per day (PPD) 0
edian years smoked (YS) 0
acks per year (PPD  YS) 0
uit (mo) 0
reoperative pulmonary function (median)
FEV1% 100%
DLCO% 86%
MVV% 85%
COG, Eastern Cooperative Oncology Group; FEV %, percentage forced
Abbreviations and Acronyms
CT  computed tomography
FDG  fluorodeoxyglucose
FDG-PET/CT fluorodeoxyglucose–positron emission
tomographic/computed tomographic
MaxSUV maximum standardized uptake value
NSCLC  non–small cell lung cancer
PET  positron emission tomography
ROI  region of interest1
onoxide; MVV%, maximum ventilation volume. *Compares smokers with those
364 The Journal of Thoracic and Cardiovascular Surgery ● Decata in the prospective database but not for entry into this specific
tudy.
adiologic Imaging
DG-PET/CT scans were performed on an integrated PET/CT
canner (GE Discovery LS PET-CT Scanner; GE, Milwaukee,
is). Patients were asked to fast for 4 hours and then subsequently
eceived 555 MBq (15 mCi) of FDG intravenously, followed by
ET after 1 hour. The scans were performed from the skull base to
he midthigh level. The computed tomographic (CT) examination
as used for attenuation correction of PET images. The scanning
ime for emission PET scanning was 5 minutes per bed position.
terative reconstruction with CT attenuation correction was per-
ormed. The most recent CT scan of the chest was also available
or visual correlation. Maximum standardized uptake value
maxSUV) of the primary tumor and of each suspicious lymph
ode station was determined by drawing regions of interest
ROIs) on the attenuation-corrected FDG-PET images around
t. It was then calculated by using the software contained within
he PET or PET/CT scanner with the following formula6:
axSUV  CCi ⁄ mL ⁄ IDCi ⁄ w(kg), where C is defined
s activity at a pixel within the tissue defined by an ROI, and ID
s defined as the injected dose per kilogram of the patient’s body
eight (w). The maxSUV within the selected ROIs was used
hroughout this study exclusively.
rocedures, Staging, and Surgical Intervention
ll patients were clinically staged with the TNM classification
ystem.7 A clinical stage was assigned for the patient based on a
ombination of CT scan results, FDG-PET/CT scan results, and
he maxSUV of the primary tumor, nodes, or both by one physi-
ian (RJC). The size of the tumor was calculated by multiplying
he greatest reported length and width of the lesion. (Because the
Former smokers,
n  112
Current smokers,
n  82 P value*
67.6  5.2 64.4 9.3 .50
58 (52%) 64 (78%) .002
54 (48%) 18 (22%)
104 (93%) 77 (94%) .90
8 (7%) 5 (6%)
0.2 0.5 .78
1.4 1.5 Not applicable
40 40
56 60
134 0
75% 71% .016
67% 68% .037
64% 71% .110
tory volume in 1 second; DLCO%, diffusing capacity of lung for carbonexpira
who never smoked.
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G
TShickness was rarely reported, we report tumor size as square
entimeters instead of cubic centimeters.) All suspicious N2, N3,
r M1 areas (maxSUV 2.5) determined either by means of
DG-PET/CT scans, CT scans, or both underwent biopsy before
ulmonary resection. Mediastinoscopy was used for biopsy of
uspicious lymph nodes in the paratracheal area (stations 2R, 4R,
L, and 4L and the superior part of the 7) and/or endoscopic
ransesophageal ultrasonographic fine-needle aspiration was used
or biopsy of suspicious posterior aortopulmonary window (n  5),
ubcarinal (n  7), periesophageal (n  8) and inferior pulmonary
igament (n  9) lymph nodes. Endoscopic ultrasonography was
erformed during conscious sedation, as previously described.8,9
Patients with suspected M1 disease in the liver, adrenal glands,
r contralateral lung underwent definitive biopsy to prove or
isprove M1 cancer. If the bone or brain was suspected to harbor
etastases, magnetic resonance imaging was considered the stan-
ard reference. If patients had biopsy-proved N3 or M1 disease,
he stage was recorded, but they were not resected. If there was no
vidence of N2 or higher disease, patients underwent thoracotomy,
ulmonary resection, and complete thoracic lymphadenectomy.
athologic review was performed by using standard techniques,
nd immunohistochemical staining was used in selected cases per
he pathologist’s discretion.
efinitions
patient was defined as having unsuspected N2 disease (false-
ABLE 2. Tumor characteristics
haracteristic
Neve
n
edian maxSUV of tumor
edian maxSUV of N2 lymph nodes that were 2.5
edian size (length  width) 2
cm2 3
istology
Squamous cell 1
Adenocarcinoma 1
Carcinoid
Bronchoalveolar
Other
athologic stage
I 2
II
III 1
T3 N1 M0
T1-T3 N2 M0
T1-T3 N3 M0
T4 Nx M0
IV
ifferentiation
Well
Moderate
Poor
ymphovascular invasion 6/2
axSUV, maximum standardized uptake value. *Compares squamous cellegative result) if the integrated FDG-PET/CT scan did not sug- t
The Journal of Thoracicest cancer in any of the N2 nodes but the patient had pathologic
roof of metastatic NSCLC cancer in at least one N2 node.
imilarly, a patient was defined as having a false-positive result if
he integrated FDG-PET-CT scan suggested disease in the N2
odes but the patient did not have disease in that node on patho-
ogic examination. Similarly, the accuracy of the T status was
etermined by the false-positive and false-negative results for the
status. For instance, if the FDG-PET suggested a tumor was T2
ut after resection it was T3 or T4, this was considered a false-
egative result. Thus if the pathologic T status was greater than the
ET-predicted T status, it was considered a false-negative result. If
ked,
2
Former smokers,
n  112
Smokers,
n  82 P value
5.1 4.9 .026
4.2 4.3 .09
.8 1.5  2.0 1.6  2.1 .923
2 3.0 cm2 3.36 cm2
%) 53 (48%) 30 (37%) .109*
%) 45 (40%) 37 (45%)
%) 3 (3%) 6 (7%)
) 2 (2%) 3 (3%)
%) 9 (8%) 6 (7%)
%) 70 (61%) 47 (57%) .186
%) 16 (14%) 11 (13%)
%) 22 (20%) 20 (24%)
3 3
16 13
2 2
1 2
%) 4 (4%) 4 (5%)
%) 14 (23%) 12 (20%) .192
%) 22 (37%) 32 (52%)
%) 24 (40%) 17 (28%)
%) 23/47 (49%) 13/29 (45%) .295
adenocarcinoma with carcinoid and bronchoalveolar carcinoma.
ABLE 3. Efficacy of integrated FDG-PET/CT for the 3
roups
Never
smoked (%)
n  52
Former
smokers (%)
n  112
Smokers (%)
n  82
P
value*
verall accuracy 83 80 64 .03
status (all) 88 84 86 .54
status (all) 89 72 79 .08
N2 96 75 72 .02
status 81 85 78 .73
DG-PET, fluorodeoxyglucose–positron emission tomography. *Comparesr smo
 5
7.3
5.6
 1
.6 cm
6 (31
8 (35
8 (14
4 (6%
6 (11
0 (38
9 (17
8 (35
3
11
3
1
5 (10
8 (38
7 (33
6 (29
0 (30hose who never smokes with current smokers.
and Cardiovascular Surgery ● Volume 132, Number 6 1365
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General Thoracic Surgery Bryant and Cerfolio
1
G
TShe pathologic T status was less than the predicted T status, it was
onsidered a false-positive result. For this calculation, T1 and T2
ere considered the same, and T3 and T4 were considered the
ame. Operative morbidity and mortality is defined as any mor-
idity or mortality occurring during the hospital stay, within 30
ays after discharge, or both.
tatistical Methods
ata were imported from the prospective database (Excel; Mi-
rosoft Corp, Seattle, Wash) into an Access database (Microsoft
orp). Analysis was performed with EpiInfo (Centers for Disease
ontrol and Prediction, Atlanta, Ga) and SAS 9.0 (SAS, Cary,
C). Accuracy (defined as the true-negative plus true positive
esults divided by the sum of all true and false results) was
etermined for FDG-PET/CT by using the pathology or biopsy
esults as the gold standard.10 Categoric values were compared by
sing analysis of variance, the 2 test, or the Fisher exact test.
ontinuous variables were compared by using the Student t test for
ormally distributed variables and the Wilcoxon test for nonnor-
ally distributed variables.
esults
atient and Tumor Characteristics
atient characteristics are shown in Table 1. Significantly
ore women were nonsmokers (P  .02). Nonsmokers had
etter percentage forced expiratory volume in 1 second (P 
016) and percentage diffusing capacity in the lung from
arbon monoxide (P  .037) values compared with those
een in smokers in this study. Tumor characteristics are
igure 1. Distribution of false-positive and false-negative results
etween smokers and nonsmokers. Positron emission tomographic/
omputed tomographic scan results were more often false negative
n patients who were current smokers.
ABLE 4. Common causes of false-positive results
No. (%)
Most common cause
results (no. of
ever smoked 23 (44) Infection (13)
uit smoking 40 (36) Infection (16)
mokers 23 (28) Granulomatous disea
366 The Journal of Thoracic and Cardiovascular Surgery ● Dechown in Table 2. Despite the lesions being of similar size,
onsmokers had a significantly greater maximum FDG up-
ake value (maxSUV) compared with smokers (7.3 vs 4.9,
espectively; P  .026). The median maxSUV value of N2
ymph nodes (excluding nodes that had a value of 2.5)
as higher for nonsmokers compared with that for smok-
rs (P  .09). The stage, histology, degree of differenti-
tion, and lymphovascular invasion were similar among
mokers and nonsmokers. Operative morbidity and mor-
ality was 19.2% and 2% in those who never smoked,
1.4% and 1% in former smokers, and 29% and 2.4% in
urrent smokers.
ccuracy
able 3 shows that the accuracy was greater for nonsmok-
rs overall and for T, N, N2, and M comparisons. Dif-
erences that achieved statistical significance were those
or overall accuracy, almost all nodal status, and N2
ymph node status. Interestingly, even former smokers
ad less accuracy for the prediction of N2 disease when
ompared with those who had never smoked (P  .004).
igure 1 shows the distribution of the false-positive and
alse-negative results for smokers, former smokers, and
hose who had never smoked. Table 4 shows the most
ommon causes of false-positive results. In those who never
moked and former smokers, it was infectious (primarily
ungal infections). Smokers had more false-negative results
han patients who quit smoking or never smoked. Figure 2
hows the inverse relationship between pack-year smoking
istory and the accuracy of FDG-PET/CT scanning. Not
urprisingly, we noted that as the maxSUV of the primary
umor, lymph node, or both decreased, the overall accuracy
or the clinical stage also decreased. Multivariate analysis
howed that status of smoking (P  .026) and maxSUV
P  .014) were independent predictors of FDG-PET/CT
ccuracy, and pack-years approached statistical significance
P  .073).
iscussion
n this prospective study we found that patients with
SCLC who continue to smoke cigarettes at the time of
heir integrated FDG-PET/CT scan have less accurate clin-
cal staging compared with those who stopped 1 month
efore and those who never smoked. Additionally, there
se-positive
nts)
Second most common cause of false-positive
results (no. of patients)
Granulomatous disease (6)
Granulomatous disease (8)of fal
patiese (12) Infection (8)
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G
TSas a dose response associated with the amount of ciga-
ettes smoked and the inaccuracy of integrated FDG-
ET-CT scans. As the cigarette pack-year history increased,
he accuracy of FDG-PET/CT scans to predict the pathology
f N2 lymph nodes decreased (P  .04).
We found that smokers have lower maxSUV values of
he primary tumor and of the N2 lymph node than those who
ever smoked. This might be attributed to differences in
athophysiology, which result in higher background FDG
racer values in smokers. A higher background uptake of
DG results in a lower maxSUV value of the pulmonary
odule or the lymph node in question (as shown in Figure 3).
he results of several studies, including this one, support
he hypothesis that a higher background value might exist
n smokers compared with nonsmokers. Miyauchi and
ahl11 showed in 1996 that smokers had significantly
ower SUV values of nodules with similar histology when
easured at both 50- to 60-minute and 60- to 70-minute
ntervals compared with their nonsmoking counterparts.
dditionally, some studies have postulated explanations
or higher background uptake in smokers compared with
igure 2. Pack-year smoking history versus accuracy of predict-
ng N2 lymph node disease.The Journal of Thoraciconsmokers. Engel and associates12 in 1996 found that
uscles with greater activity have greater uptake/back-
round compared with muscles at rest. Smokers might
se more chest musculature for breathing at rest than
onsmokers given their propensity for chronic pulmonary
ung obstruction and emphysema. Additionally, smokers
ave less blood flow to the lung13 and less oxygen
xchange, which might cause FDG to accumulate, thus
ncreasing background values. Likewise, smokers in our
tudy had significantly decreased pulmonary function test
esults and lower overall Eastern Cooperative Oncology
roup performance compared with those who never
moked.
The predictive value of integrated FDG-PET/CT is de-
endent on the maxSUV value of the individual N2 lymph
odes. In our previous study in 2005,14 we used receiver
perating characteristic curves to identify the optimal
axSUV value of mediastinal lymph nodes that best pre-
icted pathology. We found that value to be 5.3 for N2
mediastinal) lymph nodes. However, in this study we used
lower value of 2.5 so as not to miss N2 disease and thus
ccepted some false-positive results. Therefore the lower
ccuracy in smokers for N2 lymph nodes might be due to
he increased background activity, which results in a lower
axSUV of the nodes compared with that seen in those who
ever smoked.
The strengths of this study are the prospective design, the
athology-proved nodal disease with removal instead of
iopsy, the fact that the distribution of the histology of the
umors was similar among smokers and nonsmokers, and
he fact that clinical staging was performed by one individ-
al for all patients. Limitations of this study are the small
umber of patients and the fact that there might be undis-
overed differences in the molecular characteristics, bio-
hemical characteristics, or both of cancers in smokers
ompared with nonsmokers. Nonsmokers are more likely to
ave bronchoalveolar and carcinoid cancers, and because
hese types of cancers are less likely to metastasize to N2
odes, this distribution might affect the analysis. The take-
Figure 3. Simplified hypothesis of the affect of
smoking on fluorodeoxyglucose–positron emis-
sion tomographic uptake. Smokers might have a
higher background fluorodeoxyglucose uptake,
resulting in a decreased maxSUV of the nodule.
In this example, a nodule with a maxSUV of 10
would be reported with a maxSUV of 6 in a
smoker and 8 in a nonsmoker because of differ-
ences in background uptake. maxSUV, maximum
standardized uptake value.and Cardiovascular Surgery ● Volume 132, Number 6 1367
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General Thoracic Surgery Bryant and Cerfolio
1
G
TSome message from our study is that when integrated FDG-
ET/CT is used to clinically stage patients with NSCLC, the
linician should be aware that if the patient is smoking
igarettes at the time of the integrated FDG-PET/CT scan,
he maxSUV values might be lower, and the clinical accu-
acy might be lower as well.
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r David H. Harpole (Durham, NC). As usual, very nicely done
nd nicely presented. I would postulate that the difference in the
ymph nodes actually might be due to the histology of the lymph
odes, and it might be worth examining further because smokers
ave a lot of histiocytes that are just packed with material from the
moke. We have previously investigated this for a correlation with
he glut receptors. Therefore it is likely that these nodes are a little
ard to read from that standpoint and probably would have a lower
axSUV value just because there are more of these histiocytic
odes, which are full of anthracotic pigment and are not that
etabolically active, so that the tumors are a little more dispersed
n those nodes than in patients who were never smokers. The other
hing I would want to look at in those who never smoked is to see
ow many germinal centers there are in those nodes and how
acked the tumor is and so forth. I think these are excellent data.
am just trying to come up with sort of histopathologic reason why
here might be a difference in those nodes, but otherwise this is
ery nicely done.
Dr Bryant. Thank you, Dr Harpole. We agree with your
omments.
Dr Mark J. Krasna (Baltimore, Md). I am just wondering
bout the relationship between the smokers and those who never
moked versus sex. It seemed very apparent on that first slide that
ou were also looking at a group that had more women. With the
ew information on women, nonsmokers, and the prevalence of
ronchoalveolar carcinoma in that subset, can you perhaps give us
ome explanation on either how this might explain the findings or
ow you might go about trying to get rid of that possible bias in a
ollow-up study?
Dr Bryant. Thank you, Dr Krasna, for your question. There
s a propensity for bronchoalveolar carcinoma in the population
ho never smoked in this series. In our study we used a
ultivariate analysis model in which we controlled for sex, and
n doing so, we still found that the status of smoking, as well as
he maxSUV value, were independent predictors of accuracy on
ET scanning. Dose response was very close to being an
ndependent predictor, with a P value of .07, which is just
igher than the .05 level, the usual arbitrary cutoff to indicate
tatistical significance.
ember 2006
